Why We Should Treat COVID-19 Long-Hauler Syndromes with Convalescent Plasma; Contained Suppressive Exosomes Are Likely COVID Antigen-Specific
January 2024
in “
Authorea (Authorea)
”
Studysummary This source suggests that convalescent plasma therapy may interfere with early immune responses in COVID-19 due to exosomes suppressing immune cell activity, but proposes it could potentially help with COVID-19 Long Hauler Syndromes by targeting diverse antigen responses beyond just the spike protein. Our plain-language summary of this paper — not a Tressless recommendation.
The paper argues that Convalescent Plasma Therapy (CPT) should be considered for treating COVID-19 Long-Hauler Syndromes due to the presence of COVID antigen-specific suppressive exosomes in the plasma. These exosomes, which suppress antigen-presenting cells and effector T cells, may interfere with early immune responses if administered during active infection but could be beneficial for long-haulers by targeting immune reactivity to viral antigen remnants rather than residual infection. The authors suggest that CPT could be more effective than vaccines for long-haulers, as it provides a broader inhibitory influence on multiple COVID antigen-specific responses.
